Updates to Polymyalgia Rheumatica Care: Sarilumab Insights

Now Viewing

EP: 1.Updates to Polymyalgia Rheumatica Care: Sarilumab Insights

EP: 2.SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica

EP: 3.Key Patient Characteristics in the SAPHYR Trial

EP: 4.The Impact of Sarilumab on Patient Reported Outcomes

EP: 5.Polymyalgia Rheumatica: Achieving Sustained Remission

EP: 6.Updating Guidelines and Payer Access for Refractory Polymyalgia Rheumatica

EP: 7.SAPHYR Study Insights and Limitations

EP: 8.How the SAPHYR Trial Has Impacted Rheumatology Care

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

Robert Spiera, M.D., highlights the initial success of steroid therapy, yet the prolonged use poses significant challenges due to side effects. Patients, especially older individuals with comorbidities, face increased vulnerability to steroid-related toxicity, with up to 65% experiencing notable side effects. Managing polymyalgia rheumatica evolves from the initial relief to the long-term impact of steroid-related complications.

He emphasizes the dilemma: Extended steroid use addresses polymyalgia rheumatica symptoms but exacerbates health risks. Without an alternative to control disease activity, patients face functional limitations. The discussion underscores the critical need for new therapies like sarilumab to address polymyalgia rheumatica relapse during glucocorticoid tapers, offering hope for improved disease management while mitigating steroid-related challenges in long-term treatment.

This summary was AI-generated and reviewed by Managed Healthcare Executive^® staff.